Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

FDA ODAC to review Onyx’s NDA for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's new drug application (NDA) for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. ODAC will review carfilzomib at its meeting on June 20, 2012.

27 Apr 2012

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

27 Apr 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

Acetylon receives U.S. patent for ACY-1215 to treat multiple myeloma

Acetylon Pharmaceuticals Inc. today announced that it has been granted U.S. Patent 8,148,526 by the United States Patent and Trademark Office (USPTO). This patent contains fundamental composition of matter claims covering the Company's selective HDAC6 inhibitor, ACY-1215, which is currently being investigated in human clinical trials for the treatment of multiple myeloma.

21 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012

MMRF announces unique oncology research partnership

The Multiple Myeloma Research Foundation (MMRF) today announced a unique oncology research partnership. This multi-year agreement involves several partners including the Translational Genomics Research Institute (TGen), Spectrum Health, and the Van Andel Research Institute.

3 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

CIBMTR report shows higher survival rate for patients treated at RPCI's BMT program

Outcomes for patients treated through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) are among the highest in the nation. For the second consecutive year, a report compiled by the Center for International Blood and Marrow Transplant Research (CIBMTR) shows that the one-year survival rate for transplant patients treated at RPCI was significantly higher than expected, affirming RPCI's position among the elite of U.S. centers performing the procedure.

21 Mar 2012

New drug makes chemotherapy more effective in treating acute myeloid leukemia

Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

21 Mar 2012

XTL Biopharmaceuticals completes $2.4 million private placement of securities

XTL Biopharmaceuticals announced yesterday, March 18, 2012, it successfully completed a private placement of securities with foreign as well as Israeli institutional and private investors for a total of $2.4 million (NIS 9.1 million).

19 Mar 2012

TGen to present new research about multiple myeloma at AzMN conference

The Translational Genomics Research Institute (TGen) will present new research about the blood-cell cancer known as multiple myeloma at a free public conference hosted by the Arizona Myeloma Network.

12 Mar 2012

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia.

9 Mar 2012

CTI fourth quarter net loss decreases to $17.9 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011.

7 Mar 2012

EntreMed plans to establish drug development office in China

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated plans to establish an office in China to facilitate the Company's drug development and clinical trials in that country.

6 Mar 2012

Researchers discover connection between early humans and Neanderthals' genome

A striking discovery in the study of human genetics was the focus of the most-visited press release posted on EurekAlert! in 2011. Researchers found that part of the non-African human X chromosome came from Neanderthals, confirming that they interbred with early human populations.

28 Feb 2012